NeuroPace (NPCE) EBITDA Margin Growth (3y) (2023 - 2026)
NeuroPace (NPCE) EBITDA Margin Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.39 Bn | 175.10 Bn | 6.27 Bn | -343.00 |
| 2 | Stryker | 128.75 Bn | 125.87 Bn | 3.81 Bn | 17.00 |
| 3 | Medtronic | 108.59 Bn | 99.37 Bn | 6.41 Bn | 78.00 |
| 4 | Boston Scientific | 68.22 Bn | 66.77 Bn | 3.61 Bn | 487.00 |
| 5 | Edwards Lifesciences | 47.59 Bn | 43.92 Bn | 1.29 Bn | -283.00 |
| 6 | Dexcom | 28.58 Bn | 27.46 Bn | 750.30 Mn | 1,505.00 |
| 7 | GE HealthCare Technologies | 28.48 Bn | 26.20 Bn | 1.98 Bn | -184.00 |
| 8 | Smith & Nephew | 26.96 Bn | 26.39 Bn | - | - |
| 9 | Koninklijke Philips | 25.47 Bn | 22.34 Bn | 2.07 Bn | -763.00 |
| 10 | NeuroPace | 519.24 Mn | 465.26 Mn | 18.05 Mn | 3,225.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3,225.00 |
| Dec 31, 2025 | 7,044.00 |
| Sep 30, 2025 | 8,191.00 |
| Jun 30, 2025 | 7,857.00 |
| Mar 31, 2025 | 6,298.00 |
| Dec 31, 2024 | 6,496.00 |
| Sep 30, 2024 | 4,024.00 |
| Jun 30, 2024 | 411.00 |
| Mar 31, 2024 | -709.00 |
| Dec 31, 2023 | -32.00 |
| Sep 30, 2023 | -2,709.00 |
| Jun 30, 2023 | -247.00 |
| Mar 31, 2023 | -277.00 |